GO:0042586 peptide deformylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042586 peptide deformylase activity catalyzes the removal of the formyl group from N-formyl-L-methionyl peptides, producing formate and a methionyl peptide.
• Peptide deformylase (PDF) is essential for bacterial protein maturation and is a validated target for antibacterial drug discovery.
• PDF inhibitors such as actinonin and piperazic acid derivatives show in vivo activity against respiratory tract and skin pathogens.
• Human peptide deformylase can activate N-formyldipeptide-masked prodrugs, revealing a role beyond bacterial metabolism.
• Phage-encoded and bacterial peptide deformylases display similar deformylase activity and inhibitor binding clefts.
• CRISPR knockout, point mutation, and overexpression models enable functional dissection of PDF in bacteria and human cells.
Description
Peptide deformylase activity (GO:0042586) is a molecular function that removes the formyl group from the N-terminus of newly synthesized polypeptides in bacteria, a critical step in protein maturation. This activity is catalyzed by peptide deformylase (PDF), an enzyme that hydrolyzes the amide bond between the formyl group and the methionine residue, releasing formate and a methionyl peptide. Because PDF is essential for bacterial viability and is absent from the cytoplasm of most eukaryotes, it has attracted intense interest as a target for novel antibiotics. The enzyme is also found in some phages and in human mitochondria, where it may play additional roles in protein processing and prodrug activation. Understanding the molecular mechanism, regulation, and inhibitor interactions of peptide deformylase activity is therefore crucial for both basic microbiology and therapeutic development.
peptide deformylase activity At A Glance
| GO ID | GO:0042586 |
|---|---|
| GO term | peptide deformylase activity |
| Ontology | molecular_function |
| Synonym | formyl-L-methionyl peptide amidohydrolase activity; PDF activity; polypeptide deformylase activity |
| Major function | Catalyzes the removal of the formyl group from N-formyl-L-methionyl peptides, producing formate and a methionyl peptide |
| Reaction | formyl-L-methionyl peptide + H2O = formate + methionyl peptide |
| Cofactor | Fe(II) (ferredoxin-like iron center) in many bacterial PDFs |
| Inhibitors | Actinonin, piperazic acid derivatives, bromoindole derivatives |
| Related diseases | Bacterial infections (respiratory tract, skin), potential roles in mitochondrial function |
What Is GO:0042586?
According to the Gene Ontology, peptide deformylase activity (GO:0042586) is defined as the catalysis of the reaction: formyl-L-methionyl peptide + H2O = formate + methionyl peptide. In other words, it is the enzymatic removal of a formyl group from the N-terminus of a peptide, converting an N-formyl-L-methionyl peptide into a methionyl peptide and free formate. This activity is synonymous with formyl-L-methionyl peptide amidohydrolase activity, PDF activity, and polypeptide deformylase activity.
Why Is peptide deformylase activity Important in Cell Biology?
Peptide deformylase activity is essential for bacterial protein maturation and is a proven target for antibacterial therapy. Inhibitors of PDF have demonstrated in vivo efficacy against respiratory tract and skin pathogens, validating the enzyme as a druggable target. Beyond bacteria, human peptide deformylase can activate prodrugs, suggesting additional roles in drug metabolism. The enzyme is also encoded by some phages, where it contributes to phage protein processing. Thus, understanding PDF activity has broad implications for infectious disease, drug discovery, and molecular biology.
• Essential for bacterial protein maturation: PDF removes the N-terminal formyl group from nascent polypeptides, a prerequisite for further processing.
• Validated antibacterial target: PDF inhibitors show activity against respiratory tract pathogens such as Streptococcus pneumoniae and Haemophilus influenzae.
• In vivo efficacy: piperazic acid PDF inhibitors are effective in animal models of respiratory tract and skin infections.
• Prodrug activation: human PDF can cleave N-formyldipeptide masks to release active drugs.
• Phage biology: phage-encoded PDFs share similar activity and inhibitor binding with bacterial enzymes.
• Tool for inhibitor discovery: actinonin and bromoindole derivatives are used to probe PDF activity in cells.
• Potential mitochondrial role: human PDF may process mitochondrial proteins, linking to mitochondrial function.
• Broad-spectrum potential: PDF is conserved across many bacterial pathogens, making it an attractive broad-spectrum target.
• Structural insights: PDF has a unique fold with a catalytic Fe(II) center, enabling structure-based drug design.
• Research models: CRISPR knockout and point mutation models allow functional studies of PDF in various organisms.
Molecular Mechanism of peptide deformylase activity
Substrate Recognition and Binding
In simple terms: PDF recognizes and binds to the N-formyl-methionine start of a new protein chain.
Peptide deformylase specifically binds N-formyl-L-methionyl peptides, which are the initial products of bacterial translation. The enzyme's active site accommodates the formyl-methionine moiety, positioning the formyl group for hydrolysis. Structural studies show that the substrate binding cleft is highly conserved among bacterial and phage PDFs, explaining their similar activity.
Catalytic Mechanism and Metal Cofactor
In simple terms: A metal ion in the enzyme's active site helps break the bond between the formyl group and the peptide.
PDF is a metalloenzyme that typically contains a Fe(II) ion coordinated by conserved histidine and cysteine residues. The metal ion activates a water molecule, which attacks the formyl carbon, leading to the release of formate and the methionyl peptide. This mechanism is supported by inhibitor binding studies, where compounds like actinonin chelate the metal and block catalysis.
Inhibitor Binding and Selectivity
In simple terms: Drug-like molecules can fit into the enzyme's active site and stop it from working.
PDF inhibitors such as actinonin and piperazic acid derivatives bind to the active site, often interacting with the metal ion and surrounding residues. These inhibitors show selectivity for bacterial over human PDF, which is crucial for antibiotic development. Bromoindole derivatives have been evaluated for in cellulo activity, demonstrating that inhibitor binding translates to functional inhibition.
Role in Protein Maturation and Beyond
In simple terms: After PDF removes the formyl group, other enzymes can further modify the protein, and in humans PDF can also activate prodrugs.
Deformylation is a prerequisite for subsequent N-terminal processing, such as methionine excision by methionine aminopeptidase. In bacteria, this pathway is essential for protein stability and function. In humans, peptide deformylase can cleave N-formyldipeptide prodrug masks, releasing active compounds, which expands its biological roles.
Key Genes Involved in GO:0042586 peptide deformylase activity
The following genes and proteins are directly involved in peptide deformylase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| def (PDF) | Bacterial peptide deformylase; catalyzes deformylation | Essential for bacterial viability; target of antibiotics |
| fmt | Methionyl-tRNA formyltransferase; adds formyl group to Met-tRNA | Provides the substrate for PDF; part of the same pathway |
| map | Methionine aminopeptidase; removes N-terminal methionine after deformylation | Works downstream of PDF in protein maturation |
| PDF (human) | Mitochondrial peptide deformylase; activates prodrugs | Potential role in drug metabolism and mitochondrial function |
| Phage PDF | Phage-encoded peptide deformylase | Shows similar activity and inhibitor binding to bacterial PDF |
| actinonin target | Natural product inhibitor of PDF | Used as a tool compound to study PDF inhibition |
| piperazic acid derivatives | Synthetic PDF inhibitors | In vivo efficacy against respiratory and skin infections |
| bromoindole derivatives | PDF inhibitors | Evaluated for in cellulo activity |
| Vibrio parahaemolyticus PDF | Bacterial PDF from a marine pathogen | Model for studying PDF from diverse bacteria |
| Streptococcus pneumoniae PDF | PDF from a respiratory pathogen | Target for antibacterial development |
| Haemophilus influenzae PDF | PDF from a respiratory pathogen | Target for antibacterial development |
| Staphylococcus aureus PDF | PDF from a skin pathogen | Target for antibacterial development |
| Escherichia coli PDF | Well-studied model PDF | Biochemical and structural studies |
| Bacillus subtilis PDF | Gram-positive model PDF | Genetic studies of essentiality |
| Thermus thermophilus PDF | Thermophilic PDF | Structural studies |
| Pseudomonas aeruginosa PDF | PDF from an opportunistic pathogen | Antibacterial target |
| Mycobacterium tuberculosis PDF | PDF from the tuberculosis pathogen | Potential drug target |
| Helicobacter pylori PDF | PDF from a gastric pathogen | Potential drug target |
How Is peptide deformylase activity Regulated?
Peptide deformylase activity is primarily regulated at the level of gene expression and enzyme availability. In bacteria, def gene expression is constitutive but can be modulated by growth conditions. The enzyme requires Fe(II) for activity, and metal homeostasis influences its function. Inhibitor studies show that PDF activity can be blocked by small molecules, which is exploited for antibacterial therapy. In human cells, peptide deformylase is imported into mitochondria, and its activity may be regulated by mitochondrial protein import and processing. No direct eukaryotic transcriptional regulators of PDF have been well characterized, but its role in prodrug activation suggests potential regulation by drug-metabolizing pathways.
peptide deformylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| def (bacterial) | Respiratory tract infections | Knockout in S. pneumoniae; mouse infection model |
| def (bacterial) | Skin infections | Knockout in S. aureus; mouse skin infection model |
| PDF (human) | Mitochondrial dysfunction | Knockout in human cell lines; mitochondrial stress assays |
| PDF (human) | Prodrug activation | Overexpression in cancer cells; prodrug cytotoxicity assays |
| Phage PDF | Phage-bacterial interactions | Phage infection models; plaque assays |
Bacterial Infections
Peptide deformylase is essential for bacterial growth, and its inhibition leads to bacterial cell death. PDF inhibitors have shown efficacy against respiratory tract pathogens such as Streptococcus pneumoniae and Haemophilus influenzae, as well as skin pathogens like Staphylococcus aureus. This makes PDF a promising target for combating antibiotic-resistant infections.
Mitochondrial Dysfunction and Prodrug Activation
Human peptide deformylase localizes to mitochondria and can activate N-formyldipeptide-masked prodrugs. This suggests a role in mitochondrial protein processing and drug metabolism, with potential implications for mitochondrial diseases and cancer therapy.
Phage-Bacterial Interactions
Phage-encoded peptide deformylases share similar activity and inhibitor binding with bacterial enzymes, indicating a role in phage protein maturation. This highlights the evolutionary conservation of PDF and its potential impact on phage therapy.
From peptide deformylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is PDF essential for bacterial viability? | CRISPR knockout of def in S. pneumoniae or E. coli |
| How does PDF inhibition affect bacterial growth? | Point mutation in def active site; inhibitor susceptibility testing |
| Can human PDF activate prodrugs? | Knock-in of human PDF into PDF-deficient cells; prodrug assays |
| What is the role of PDF in phage biology? | Overexpression of phage PDF in bacteria; phage infection |
| How does PDF contribute to mitochondrial function? | Knockout of human PDF in cell lines; mitochondrial respiration assays |
| Can PDF inhibitors be optimized for in vivo efficacy? | Knock-in of resistant PDF mutants; animal infection models |
How to Study the peptide deformylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Colorimetric PDF assay | Formate release from N-formyl-methionyl peptide | High-throughput inhibitor screening |
| Mass spectrometry | Deformylated peptide products | In cellulo inhibitor activity |
| X-ray crystallography | Three-dimensional structure of PDF-inhibitor complexes | Structure-based drug design |
| CRISPR knockout | Loss of PDF function | Essentiality studies in bacteria |
| Site-directed mutagenesis | Effect of point mutations on PDF activity | Mechanistic studies |
| Overexpression | Increased PDF levels | Prodrug activation studies |
| Phage infection assays | Phage PDF function | Phage biology |
| Animal infection models | In vivo efficacy of PDF inhibitors | Drug development |
Biochemical Assays for PDF Activity
Peptide deformylase activity can be measured using synthetic N-formyl-methionyl peptide substrates and detecting the release of formate or the formation of methionyl peptide. Colorimetric or fluorogenic assays are commonly used for high-throughput inhibitor screening.
Mass Spectrometry-Based Evaluation
Mass spectrometry allows direct detection of deformylated products and can assess in cellulo activity of PDF inhibitors such as actinonin and bromoindole derivatives. This method provides quantitative and structural information.
Structural Biology
X-ray crystallography and NMR spectroscopy have been used to determine the structure of PDF in complex with inhibitors, revealing key interactions with the catalytic metal and substrate binding pocket. These studies guide structure-based drug design.
Genetic and CRISPR Approaches
CRISPR knockout, point mutation, and overexpression models enable functional studies of PDF in bacteria and human cells. These models help determine essentiality, inhibitor resistance, and roles in prodrug activation.
How CRISPR Can Be Used to Study GO:0042586 peptide deformylase activity
Knockout
CRISPR knockout of the def gene in bacteria such as Streptococcus pneumoniae or Staphylococcus aureus can determine whether PDF is essential for viability. Conditional knockouts allow studying PDF function in human cells, particularly for mitochondrial roles.
Point Mutation
Introducing point mutations in the PDF active site (e.g., metal-coordinating residues) via CRISPR can dissect the catalytic mechanism and identify residues critical for inhibitor binding. Such mutants are valuable for resistance studies.
Knock-in
Knock-in of human PDF into PDF-deficient bacterial or mammalian cells can test functional conservation and prodrug activation. Tagged knock-in (e.g., GFP-PDF) enables localization studies.
Overexpression
CRISPR activation or plasmid-based overexpression of PDF can increase deformylase activity, useful for prodrug activation studies and for producing large amounts of enzyme for biochemical assays.
How EDITGENE Supports peptide deformylase activity Research
Researchers studying peptide deformylase activity-related genes often need to determine whether a candidate gene is causally involved in bacterial viability, inhibitor resistance, or prodrug activation. EDITGENE provides comprehensive CRISPR-based services to create precise cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for peptide deformylase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PDF Knockout HEK293 Cell Line | EDJ-KQ51615 | Human | 64146 | Details Get a Quote |
| PDF Knockout HeLa Cell Line | EDJ-KQ57037 | Human | 64146 | Details Get a Quote |
| PDF Knockout A-549 Cell Line | EDJ-KQ65543 | Human | 64146 | Details Get a Quote |
| PDF Knockout HCT 116 Cell Line | EDJ-KQ73975 | Human | 64146 | Details Get a Quote |
Frequently Asked Questions About peptide deformylase activity
What is peptide deformylase activity?
Peptide deformylase activity (GO:0042586) is the enzymatic removal of a formyl group from N-formyl-L-methionyl peptides, producing formate and a methionyl peptide.
What genes are involved in peptide deformylase activity?
The primary gene is def (PDF), which encodes peptide deformylase. Other related genes include fmt (methionyl-tRNA formyltransferase) and map (methionine aminopeptidase).
Why is peptide deformylase a good antibiotic target?
PDF is essential for bacterial protein maturation and is absent from most eukaryotic cytoplasm, making it a selective target for antibiotics.
What inhibitors target peptide deformylase?
Actinonin, piperazic acid derivatives, and bromoindole derivatives are known PDF inhibitors with antibacterial activity.
Does human peptide deformylase exist?
Yes, human PDF is localized to mitochondria and can activate N-formyldipeptide-masked prodrugs.
How can I study peptide deformylase activity in the lab?
Common methods include colorimetric assays, mass spectrometry, X-ray crystallography, and CRISPR-based genetic models.
What diseases are associated with peptide deformylase?
Bacterial infections such as respiratory tract and skin infections are the primary diseases linked to PDF, as it is a target for antibiotics.
Can CRISPR be used to study peptide deformylase?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to study PDF function and inhibitor resistance.
What is the reaction catalyzed by peptide deformylase?
The reaction is: formyl-L-methionyl peptide + H2O = formate + methionyl peptide.
Are there phage-encoded peptide deformylases?
Yes, some phages encode PDFs that display similar deformylase activity and inhibitor binding to bacterial enzymes.
Conclusion
Peptide deformylase activity (GO:0042586) is a fundamental enzymatic function in bacterial protein maturation and a validated target for antibacterial drug discovery. Its mechanism, inhibitors, and roles in prodrug activation and phage biology are well documented. CRISPR-based models offer powerful tools to further dissect PDF function and develop new therapeutics.
References
- 1. Boularot A et al.. 2004. Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors.. Curr Opin Investig Drugs 5(8):809-22 PMID: 15600237
- 2. Aubart K et al.. 2006. Peptide deformylase inhibitors.. Prog Med Chem 44:109-43 PMID: 16697896
- 3. Spletstoser JT et al.. 2019. Discovery of piperazic acid peptide deformylase inhibitors with in vivo activity for respiratory tract and skin infections.. Bioorg Med Chem Lett 29(16):2410-2414 PMID: 31160176
- 4. East SP et al.. 2004. Peptide deformylase inhibitors with activity against respiratory tract pathogens.. Bioorg Med Chem Lett 14(1):59-62 PMID: 14684298
- 5. Geißen R et al.. 2025. Activation of N-Formyldipeptide-Masked Prodrugs by Human Peptide Deformylase.. ACS Chem Biol 20(9):2171-2179 PMID: 40788532
- 6. Grzela R et al.. 2018. Peptide deformylases from Vibrio parahaemolyticus phage and bacteria display similar deformylase activity and inhibitor binding clefts.. Biochim Biophys Acta Proteins Proteom 1866(2):348-355 PMID: 29101077
- 7. Huntington KM et al.. 2000. Synthesis and antibacterial activity of peptide deformylase inhibitors.. Biochemistry 39(15):4543-51 PMID: 10758004
- 8. Bachmann N et al.. 2026. Towards selective peptide deformylase inhibitors: A mass spectrometry-based evaluation of in cellulo activity of actinonin and bromoindole derivatives.. Eur J Med Chem 308:118678 PMID: 41719802
